About the Authors
- Deborah Friedman
-
* E-mail: Deborah_Friedman@NYMC.edu (DF); Adam.Bloomfield@astrazeneca.com (AB)
Affiliation Department of Pediatrics, New York Medical College, Valhalla, NY, United States of America
- Jon Fryzek
-
Affiliation EpidStat Institute, Rockville, MD, United States of America
- Xiaohui Jiang
-
Affiliation EpidStat Institute, Rockville, MD, United States of America
- Adam Bloomfield
-
* E-mail: Deborah_Friedman@NYMC.edu (DF); Adam.Bloomfield@astrazeneca.com (AB)
Affiliation AstraZeneca, Gaithersburg, MD, United States of America
- Christopher S. Ambrose
-
Affiliation AstraZeneca, Gaithersburg, MD, United States of America
- Pierre C. Wong
-
Affiliation Division of Cardiology, Children's Hospital, Los Angeles, CA, United States of America
Competing Interests
This research was funded by AstraZeneca. JF and XJ provided consultant/research support for AstraZeneca. AB and CSA are employees of AstraZeneca. Palivizumab is marketed by MedImmune, a specialty care division of AstraZeneca. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: DF JF XJ AB CSA PCW. Data curation: JF XJ. Formal analysis: XJ. Funding acquisition: AB CSA. Investigation: DF JF XJ AB CSA PCW. Methodology: DF JF XJ AB CSA PCW. Project administration: AB CSA. Resources: AB CSA. Software: JF XJ. Supervision: DF JF XJ AB CSA PCW. Validation: JF XJ. Visualization: DF JF XJ AB CSA PCW. Writing – original draft: JF XJ AB CSA. Writing – review & editing: DF JF XJ AB CSA PCW.